Global Robotics Institute, Florida Hospital Celebration Health, USA.
BJU Int. 2012 Feb;109(3):426-33. doi: 10.1111/j.1464-410X.2011.010401.x. Epub 2011 Aug 18.
To describe a technical modification during robotic-assisted simple prostatectomy (RASP) aiming to decrease perioperative blood loss, shorten the length of hospital stay and eliminate the need of postoperative continuous bladder irrigation. To describe perioperative outcomes, pathological findings and functional outcomes of our single-surgeon series using this technique.
We analysed six consecutive patients who underwent RASP using our technical modification between February and September 2010. Transrectal ultrasonography (TRUS) guided prostate biopsy was performed in all cases and revealed benign prostatic hyperplasia in two cases and benign prostatic hyperplasia plus chronic prostatitis in four cases. The mean estimated prostate volume in the TRUS was 157 ± 74 (range 90-300) mL and the average preoperative International Prostate Symptom score was 19.8 ± 9.6 (10-32). Two patients were in urinary retention before surgery. Our technique of RASP includes the standard operative steps reported during open and laparoscopic simple prostatectomy; however, with the addition of some technical modifications during the reconstructive part of the procedure. Following the resection of the adenoma, instead of performing the classical 'trigonization' of the bladder neck and closure of the prostatic capsule, we propose three modified surgical steps: plication of the posterior prostatic capsule, a modified van Velthoven continuous vesico-urethral anastomosis and, finally, suture of the anterior prostatic capsule to the anterior bladder wall.
The patients' average age was 69 ± 4.9 (63-74) years; the mean estimated blood loss was 208 ± 66 (100-300) mL and the mean operative time was 90 ± 17.6 (75-120) min. All patients were discharged on postoperative day 1 without the need of continuous bladder irrigation at any time after RASP. No blood transfusion or perioperative complications were reported. The mean weight of the surgical specimen was 145 ± 41.6 (84-186) g. Histopathological evaluation revealed benign prostatic hyperplasia plus chronic prostatitis in five patients and prostatic adenocarcinoma (Gleason score 3+3, pT1a) with negative surgical margins in one patient. The mean serum prostate-specific antigen level decreased from 7 ± 2.5 (4.2-11) ng/mL preoperatively to 1.05 ± 0.8 (0.2-2.5) after RASP. Significant improvement from baseline was reported in the average International Prostate Symptom score (average preoperative vs postoperative, 19.8 ± 9.6 vs 5.5 ± 2.5, P= 0.01) and in mean maximum urine flow (average preoperative vs postoperative 7.75 ± 3.3 vs 19 ± 4.5 mL/s, P= 0.019) at 2 months after RASP. All patients were continent (defined as the use of no pads) at 2 months after RASP.
Our modified technique of RASP is a safe and feasible option for treatment of lower urinary tract symptoms caused by large prostatic adenomas. Potential advantages of our technique include reduced blood loss, lower blood transfusion rates and shorter length of hospital stay with no need of postoperative continuous bladder irrigation. Larger series with longer follow-up are necessary to determine long-term outcomes in comparison to open simple prostatectomy or to the standard technique of RASP.
描述一种机器人辅助单纯前列腺切除术(RASP)中的技术改良方法,旨在减少围手术期出血、缩短住院时间并消除术后持续膀胱冲洗的需要。描述我们使用该技术的单外科医生系列的围手术期结果、病理发现和功能结果。
我们分析了 2010 年 2 月至 9 月期间接受 RASP 技术改良的 6 例连续患者。所有病例均进行经直肠超声(TRUS)引导前列腺活检,其中 2 例为良性前列腺增生,4 例为良性前列腺增生合并慢性前列腺炎。TRUS 估计前列腺体积平均为 157 ± 74(90-300)mL,术前国际前列腺症状评分平均为 19.8 ± 9.6(10-32)。术前有 2 例患者有尿潴留。我们的 RASP 技术包括在开放性和腹腔镜单纯前列腺切除术中报告的标准手术步骤;然而,在手术重建部分增加了一些技术改良。在切除腺瘤后,我们建议进行三种改良手术步骤,而不是进行经典的膀胱颈部“三角化”和前列腺包膜关闭:前列腺后包膜折叠、改良的 van Velthoven 连续膀胱-尿道吻合术,最后,将前列腺前包膜缝合到前膀胱壁上。
患者的平均年龄为 69 ± 4.9(63-74)岁;平均估计出血量为 208 ± 66(100-300)mL,平均手术时间为 90 ± 17.6(75-120)min。所有患者均在术后第 1 天出院,RASP 后无需任何时间进行持续膀胱冲洗。无输血或围手术期并发症发生。手术标本的平均重量为 145 ± 41.6(84-186)g。组织病理学评估显示,5 例为良性前列腺增生合并慢性前列腺炎,1 例为前列腺腺癌(Gleason 评分 3+3,pT1a),切缘阴性。术前血清前列腺特异性抗原水平从 7 ± 2.5(4.2-11)ng/mL 降至术后 1.05 ± 0.8(0.2-2.5)ng/mL。术后 2 个月,国际前列腺症状评分(平均术前 vs 术后,19.8 ± 9.6 vs 5.5 ± 2.5,P=0.01)和最大尿流率(平均术前 vs 术后,7.75 ± 3.3 vs 19 ± 4.5 mL/s,P=0.019)有显著改善。术后 2 个月,所有患者均能控制(定义为不使用尿垫)。
我们改良的 RASP 技术是治疗大前列腺腺瘤引起的下尿路症状的一种安全可行的选择。我们的技术的潜在优势包括减少出血、降低输血率和缩短住院时间,且无需术后持续膀胱冲洗。需要更大的系列和更长的随访时间来确定与开放性单纯前列腺切除术或 RASP 标准技术相比的长期结果。